Seres Therapeutics: Here We Go Again
Summary
- The microbiome has arrived as a significant area of opportunity for new treatments of infectious and chronic conditions. While the importance of the microbiome is clear, validated products remain elusive.
- Seres Therapeutics is close to achieving FDA approval of SER-109 for preventing recurrence of C. difficile infection. This would be the first microbiome product approved by the FDA.
- Nestle is confident about SER-109; it acquired US & Canadian rights to achieve global rights to market these products. Nestle paid $175 million (and more coming) for these rights.
- The share price crashed when SER-287 failed in an Ulcerative Colitis trial; a new trial with SER-301 is planned.
- Seres has a big (and opaque) cash burn, but it is well funded to achieve SER-109 approval. If that doesn’t happen, all bets are off.
Analyst’s Disclosure:I/we have a beneficial long position in the shares of MCRB either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.